Valsartan case containing carcinogenic substances will bring negative impacts

Started with the Valsartan case, conflicts between doctors and pharmacists have led to discussions about rebates for pharmaceutical companies.

Doctors have opposed to the international proprietary names – this has been argued by them for a while – because they could not trust bioequivalently tested generic drugs in regards based on the case of Valsartan ingredients containing carcinogenic subs...